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Reye's syndrome and short-chain fatty acids 
To the Editor: In measured plasma levels of short-chain fatty 
acids in Reye's syndrome, McArthur et al1 found a significant 
increase only of propionic acid levels in patients with moderate or 
severe clinical signs, and of isovaleric acid concentrations in 
patients with moderate signs; isobutyric, n-butyric, n-valeric and 
caproic acid concentrations showed no elevation, but tended to 
values lower than those of controls. Of these six acids, increased 
levels of only isovaleric and propionic acids occur in disorders of 
biotin-dependent carboxylases. Isovaleric acid is elevated in cases 
of diminished activity of 3-methylcrotonyl-CoA carboxylase; pro-
pionic acid is elevated in propionyl-CoA carboxylase deficiency.2 
The most prominent finding* in a postmortem examination of 
mitochondrial liver enzymes in patients with Reye's syndrome 
was reduction of pyruvate carboxylase activity, another bio tin-
dependent carboxylase, and this could explain the lactic acidemia 
of Reye's syndrome.1-4 We found a marked reduction of plasma 
levels of biotin (caused by intake of anticonvulsants) and elevation 
of biotin-dependent short-chain fatty acids in the urine of seizure 
patients. r ,ß Because Reye's syndrome is sometimes a fatal com-
plication of anticonvulsant therapy,7 the possible relation between 
biotin status or biotin-dependent carboxylases should be consid-
ered in investigations of Reye's syndrome. 
Klaus-Henning Krause, MD 
Peter Berlit, MD 
Heidelberg, F.R.G. 
Jean-Pierre Bonjour, PhD 
Basle, Switzerland 
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Reply from the Authors: Krause, Berlit, and Bonjour offer an 
interesting explanation for the origin of short-chain fatty acide-
mia in Reye's syndrome (RS). To our knowledge, plasma biotin 
levels have not been measured in Reye patients, and the possibility 
of drug-induced biotin deficiency cannot be excluded. Neverthe-
less, some clinical and biochemical findings seem to be inconsis-
tent with this mechanism as the primary cause of Reye's 
syndrome. 
Clinically manifest biotin deficiency is rare, reported with 
prolonged parenteral alimentation or excessive ingestion of raw 
egg white.1 - The typical manifestations (including seborrheic der-
matitis, alopecia, and conjunctivitis) are slow to develop and 
respond promptly to biotin therapy. Conversely, Reye's encepha-
lopathy is manifested by pernicious vomiting, behavior changes, 
and agitation that are sometimes followed by decorticate or 
decerebrate coma. Flaccid coma and death may result from brain-
stem compression due to intracranial hypertension. 
Several chemical agents (including valproic acid) have been 
incriminated as causes of a "Reye-like syndrome." However, none 
of them has been documented as a cause of the salient ultrastruc-
tural, biochemical, and histochemical changes in liver that are 
characteristic of Reye's syndrome and which collectively define it 
as a distinct disease. In two patients with fatal hepatic failure after 
use of valproic acid, the liver injury differed from the lesion of RS 
on histopathologic examination.:! Hepatic pyruvate carboxylase 
activity is decreased in RS, but the biotin-independent hepatic 
mitochondrial enzymes, such as glutamic dehydrogenase and 
monoamine oxidase, are also decreased.4 These alterations are 
probably due to a general injury of hepatic mitochondria. 
Given the fasted state of the RS patient before admission and 
the high rate of protein catabolism/' the relatively modest eleva-
tions of short-chain fatty acids would be expected. 
Robert A. Mitchell, PhD 
Brian McArthur, MS 
Ashok P. Sarnaik, MB, BS 
Detroit, Ml 
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